Table of Content

1. Executive Summary
   1.1. Global Acute Myeloid Leukemia Treatment Market Snapshot, 2024 and 2031
   1.2. Market Opportunity Assessment, 2024 - 2031, US$ Bn
   1.3. Key Market Trends
   1.4. Future Market Projections
   1.5. Premium Market Insights
   1.6. Industry Developments and Key Market Events
   1.7. PMR Analysis and Recommendations
2. Market Overview
   2.1. Market Scope and Definition
   2.2. Market Dynamics
       2.2.1. Drivers
       2.2.2. Restraints
       2.2.3. Opportunity
       2.2.4. Challenges
       2.2.5. Key Trends
   2.3. Macro-Economic Factors
       2.3.1. Global Sectorial Outlook
       2.3.2. Global GDP Growth Outlook
       2.3.3. Global Healthcare Spending Outlook
   2.4. COVID-19 Impact Analysis
   2.5. Forecast Factors - Relevance and Impact
3. Value Added Insights
   3.1. Epidemiology - Disease Prevalence and Incidence
   3.2. Technology Assessment
   3.3. Regulatory Landscape
   3.4. Value Chain Analysis
   3.5. Key Deals and Mergers
   3.6. PESTLE Analysis
   3.7. Porter’s Five Force Analysis
4. Global Acute Myeloid Leukemia Treatment Market Outlook: Historical (2018 - 2023) and Forecast (2024 - 2031)
   4.1. Key Highlights
       4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
       4.1.2. Absolute $ Opportunity
   4.2. Market Size (US$ Bn) Analysis and Forecast
       4.2.1. Historical Market Size (US$ Bn) Analysis, 2018-2022
       4.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2023-2031
   4.3. Global Acute Myeloid Leukemia Treatment Market Outlook: Disease
       4.3.1. Introduction / Key Findings
       4.3.2. Historical Market Size (US$ Bn) Analysis, By Disease, 2018 - 2022
       4.3.3. Current Market Size (US$ Bn) Analysis and Forecast, By Disease, 2023 - 2031
           4.3.3.1. Myeloblastic Leukemia
           4.3.3.2. Myelomonocytic
           4.3.3.3. Leukemia
           4.3.3.4. Promyelocytic Leukemia
   4.4. Market Attractiveness Analysis: Disease
   4.5. Global Acute Myeloid Leukemia Treatment Market Outlook: Treatment
       4.5.1. Introduction / Key Findings
       4.5.2. Historical Market Size (US$ Bn) Analysis, By Treatment, 2018 - 2022
       4.5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Treatment, 2023 - 2031
           4.5.3.1. Pharmaceutical companies
           4.5.3.2. Biotechnology companies
           4.5.3.3. Research institutions
           4.5.3.4. Hospitals and clinics
   4.6. Market Attractiveness Analysis: Treatment
   4.7. Global Acute Myeloid Leukemia Treatment Market Outlook: Route of Administration
       4.7.1. Introduction / Key Findings
       4.7.2. Historical Market Size (US$ Bn) Analysis, By Route of Administration, 2018 - 2022
       4.7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2023 - 2031
           4.7.3.1. Parenteral
           4.7.3.2. Oral
   4.8. Market Attractiveness Analysis: Route of Administration
5. Global Acute Myeloid Leukemia Treatment Market Outlook: Region
   5.1. Key Highlights
   5.2. Historical Market Size (US$ Bn) Analysis, By Region, 2018 - 2022
   5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Region, 2023 - 2031
       5.3.1. North America
       5.3.2. Europe
       5.3.3. East Asia
       5.3.4. South Asia and Oceania
       5.3.5. Latin America
       5.3.6. Middle East & Africa
   5.4. Market Attractiveness Analysis: Region
6. North America Acute Myeloid Leukemia Treatment Market Outlook: Historical (2018 - 2023) and Forecast (2024 - 2031)
   6.1. Key Highlights
   6.2. Historical Market Size (US$ Bn) Analysis, By Market, 2018 - 2022
       6.2.1. By Country
       6.2.2. By Disease
       6.2.3. By Treatment
       6.2.4. By Route of Administration
   6.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2023 - 2031
       6.3.1. U.S.
       6.3.2. Canada
   6.4. Current Market Size (US$ Bn) Analysis and Forecast, By Disease, 2023 - 2031
       6.4.1. Myeloblastic Leukemia
       6.4.2. Myelomonocytic
       6.4.3. Leukemia
       6.4.4. Promyelocytic Leukemia
   6.5. Market Attractiveness Analysis
   6.6. Current Market Size (US$ Bn) Analysis and Forecast, By Treatment, 2023 - 2031
       6.6.1. Chemotherapy
       6.6.2. Targeted Therapy
       6.6.3. Immunotherapy
   6.7. Market Attractiveness Analysis
   6.8. Current Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2023 - 2031
       6.8.1. Parenteral
       6.8.2. Oral
   6.9. Market Attractiveness Analysis
7. Europe Acute Myeloid Leukemia Treatment Market Outlook: Historical (2018 - 2023) and Forecast (2024 - 2031)
   7.1. Key Highlights
   7.2. Historical Market Size (US$ Bn) Analysis, By Market, 2018 - 2022
       7.2.1. By Country
       7.2.2. By Disease
       7.2.3. By Treatment
       7.2.4. By Route of Administration
   7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2023 - 2031
       7.3.1. Germany
       7.3.2. France
       7.3.3. U.K.
       7.3.4. Italy
       7.3.5. Spain
       7.3.6. Russia
       7.3.7. Türkiye
       7.3.8. Rest of Europe
   7.4. Current Market Size (US$ Bn) Analysis and Forecast, By Disease, 2023 - 2031
       7.4.1. Myeloblastic Leukemia
       7.4.2. Myelomonocytic
       7.4.3. Leukemia
       7.4.4. Promyelocytic Leukemia
   7.5. Market Attractiveness Analysis
   7.6. Current Market Size (US$ Bn) Analysis and Forecast, By Treatment, 2023 - 2031
       7.6.1. Chemotherapy
       7.6.2. Targeted Therapy
       7.6.3. Immunotherapy
   7.7. Market Attractiveness Analysis
   7.8. Current Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2023 - 2031
       7.8.1. Parenteral
       7.8.2. Oral
   7.9. Market Attractiveness Analysis
8. East Asia Acute Myeloid Leukemia Treatment Market Outlook: Historical (2018 - 2023) and Forecast (2024 - 2031)
   8.1. Key Highlights
   8.2. Historical Market Size (US$ Bn) Analysis, By Market, 2018 - 2022
       8.2.1. By Country
       8.2.2. By Disease
       8.2.3. By Treatment
       8.2.4. By Route of Administration
   8.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2023 - 2031
       8.3.1. China
       8.3.2. Japan
       8.3.3. South Korea
   8.4. Current Market Size (US$ Bn) Analysis and Forecast, By Disease, 2023 - 2031
       8.4.1. Myeloblastic Leukemia
       8.4.2. Myelomonocytic
       8.4.3. Leukemia
       8.4.4. Promyelocytic Leukemia
   8.5. Market Attractiveness Analysis
   8.6. Current Market Size (US$ Bn) Analysis and Forecast, By Treatment, 2023 - 2031
       8.6.1. Chemotherapy
       8.6.2. Targeted Therapy
       8.6.3. Immunotherapy
   8.7. Market Attractiveness Analysis
   8.8. Current Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2023 - 2031
       8.8.1. Parenteral
       8.8.2. Oral
   8.9. Market Attractiveness Analysis
9. South Asia & Oceania Acute Myeloid Leukemia Treatment Market Outlook: Historical (2018 - 2023) and Forecast (2024 - 2031)
   9.1. Key Highlights
   9.2. Historical Market Size (US$ Bn) Analysis, By Market, 2018 - 2022
       9.2.1. By Country
       9.2.2. By Disease
       9.2.3. By Treatment
       9.2.4. By Route of Administration
   9.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2023 - 2031
       9.3.1. India
       9.3.2. Southeast Asia
       9.3.3. ANZ
       9.3.4. Rest of South Asia & Oceania
   9.4. Current Market Size (US$ Bn) Analysis and Forecast, By Disease, 2023 - 2031
       9.4.1. Myeloblastic Leukemia
       9.4.2. Myelomonocytic
       9.4.3. Leukemia
       9.4.4. Promyelocytic Leukemia
   9.5. Market Attractiveness Analysis
   9.6. Current Market Size (US$ Bn) Analysis and Forecast, By Treatment, 2023 - 2031
       9.6.1. Chemotherapy
       9.6.2. Targeted Therapy
       9.6.3. Immunotherapy
   9.7. Market Attractiveness Analysis
   9.8. Current Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2023 - 2031
       9.8.1. Parenteral
       9.8.2. Oral
   9.9. Market Attractiveness Analysis
10. Latin America Acute Myeloid Leukemia Treatment Market Outlook: Historical (2018 - 2023) and Forecast (2024 - 2031)
   10.1. Key Highlights
   10.2. Historical Market Size (US$ Bn) Analysis, By Market, 2018 - 2022
       10.2.1. By Country
       10.2.2. By Disease
       10.2.3. By Treatment
       10.2.4. By Route of Administration
   10.3. Current Market Size (US$ Bn) Analysis and Forecast, By Disease, 2023 - 2031
       10.3.1. Myeloblastic Leukemia
       10.3.2. Myelomonocytic
       10.3.3. Leukemia
       10.3.4. Promyelocytic Leukemia
   10.4. Market Attractiveness Analysis
   10.5. Current Market Size (US$ Bn) Analysis and Forecast, By Treatment, 2023 - 2031
       10.5.1. Chemotherapy
       10.5.2. Targeted Therapy
       10.5.3. Immunotherapy
   10.6. Market Attractiveness Analysis
   10.7. Current Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2023 - 2031
       10.7.1. Parenteral
       10.7.2. Oral
   10.8. Market Attractiveness Analysis
11. Middle East & Africa Acute Myeloid Leukemia Treatment Market Outlook: Historical (2018 - 2023) and Forecast (2024 - 2031)
   11.1. Key Highlights
   11.2. Historical Market Size (US$ Bn) Analysis, By Market, 2018 - 2022
       11.2.1. By Country
       11.2.2. By Disease
       11.2.3. By Treatment
       11.2.4. By Route of Administration
   11.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2023 - 2031
       11.3.1. GCC Countries
       11.3.2. Egypt
       11.3.3. South Africa
       11.3.4. Northern Africa
       11.3.5. Rest of Middle East & Africa
   11.4. Current Market Size (US$ Bn) Analysis and Forecast, By Disease, 2023 - 2031
       11.4.1. Myeloblastic Leukemia
       11.4.2. Myelomonocytic
       11.4.3. Leukemia
       11.4.4. Promyelocytic Leukemia
   11.5. Market Attractiveness Analysis
   11.6. Current Market Size (US$ Bn) Analysis and Forecast, By Treatment, 2023 - 2031
       11.6.1. Chemotherapy
       11.6.2. Targeted Therapy
       11.6.3. Immunotherapy
   11.7. Market Attractiveness Analysis
   11.8. Current Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2023 - 2031
       11.8.1. Parenteral
       11.8.2. Oral
   11.9. Market Attractiveness Analysis
12. Competition Landscape
   12.1. Market Share Analysis, 2023
   12.2. Market Structure
       12.2.1. Competition Intensity Mapping By Market
       12.2.2. Competition Dashboard
   12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
       12.3.1. Astellas Pharma Inc.
           12.3.1.1. Overview
           12.3.1.2. Segments and Products
           12.3.1.3. Key Financials
           12.3.1.4. Market Developments
           12.3.1.5. Market Strategy
       12.3.2. Bristol Myers Squibb Company
       12.3.3. Celgene Corporation
       12.3.4. Daiichi Sankyo Company, Limited
       12.3.5. Jazz Pharmaceuticals, plc
       12.3.6. Novartis AG
       12.3.7. Otsuka Pharmaceuticals Co., Ltd.
       12.3.8. Pfizer, Inc.
       12.3.9. Rigel Pharmaceuticals, Inc.
       12.3.10. Merck & Co., Inc.
       12.3.11. Sanofi
13. Appendix
   13.1. Research Methodology
   13.2. Research Assumptions
   13.3. Acronyms and Abbreviations